Objective To evaluate the efficacy of the non-steroidal antiinflammatory drug, meloxicam, in alleviating pain and inflammation and on production-related variables in a model of sterile acute inflammation in sheep.
Objective To evaluate the efficacy of the non-steroidal antiinflammatory drug, meloxicam, in alleviating pain and inflammation and on production-related variables in a model of sterile acute inflammation in sheep.
Methods Groups of 12 mature Merino ewes received 0, 0.5, 1.0 or 1.5 mg/kg meloxicam subcutaneously 90 min before injection of 0.1 mL turpentine subcutaneously on the anterior aspect of the proximal phalanx of a forelimb. Pain-and inflammation-related variables were assessed at −18, 3, 6, 9, 12, 24, 48 and 72 h relative to meloxicam administration. Daily feed intake and body weight change 7 days later were also assessed. Pain-related variables measured were weight borne on each forelimb, lameness score, time each forelimb was raised in a 20-s interval and tolerance to a noxious mechanical stimulus. Inflammation-related variables measured were skin temperature, limb circumference, body temperature, plasma haptoglobin concentration and peripheral blood leucocyte parameters.
Results Meloxicam was effective in improving all pain-related variables. A dose-dependent response was seen between 0 and 1.0 mg/kg, with no additional benefit provided by 1.5 mg/kg. At a dose rate of 1.0 mg/kg, meloxicam improved weight borne on the turpentine-treated limb by 14%, reduced the time the treated limb was held in a non-weight-bearing posture by 46%, reduced the lameness score by 58% and improved tolerance to pressure by 52%. No significant effects of meloxicam on inflammatory variables or appetite were observed.
Conclusions Using a validated pain model, the data suggested that 1.0 mg/kg meloxicam provided significant analgesic benefits to sheep.
Keywords animal welfare; meloxicam; non-steroidal antiinflammatory drug; oil of turpentine Abbreviations AUC, area under the curve; COX-2, cyclooxygenase-2; CV, coefficient of variation; NSAID, non-steroidal anti-inflammatory drug; PGE 2 , prostaglandin E 2 ; SEM, standard error of the mean A primary ethical responsibility of veterinarians and animal producers is to avoid pain and when pain is unavoidable, to attempt to control it. It is the unfortunate nature of modern production systems that some routine husbandry procedures predictably cause pain in farmed animals. In sheep, surgical husbandry procedures such as mulesing, castration and tail docking are commonly performed and have been shown to be associated with behavioural and physiological pain responses, and significant tissue inflammation. 1, 2 Additionally, unpredictable pain requiring treatment may occur associated with infections such as foot rot and mastitis or adventitious trauma. 3 Historically, analgesic treatment options for sheep, which are a significant production animal species in Australia and many other developed countries, have lagged behind those for other major species. In cattle and swine, nonsteroidal anti-inflammatory drugs (NSAIDs) have been registered for analgesic treatment and have a long history of safe and effective use; however, at the time the current study was initiated no NSAID was registered for sheep, in Australia or elsewhere. To address this deficiency in the therapeutic armamentarium of sheep veterinarians and producers, we have undertaken a series of studies into the efficacy of the NSAID meloxicam in sheep.
Assessment of analgesic efficacy can be challenging under field conditions. As an alternative to field studies, a well-defined and validated pain model allows objective quantification of pain-related variables under controlled conditions. To be relevant, the selected pain model must stimulate a physiological response that is similar in nature to that seen under natural challenge conditions. We developed a model of local and systemic inflammation and shortterm pain in sheep, with the objective of quantifying the efficacy of NSAIDs. 4 The model involves subcutaneous injection of 0.1 mL of oil of turpentine on the proximal phalanx above the coronet of non-pregnant female sheep trained to stand for measurement of weight exerted through each forelimb (force plate analysis). 4 Skin temperature, circumference of the forelimb, sensitivity of the forelimb to pressure and lameness scores are also measured to assess local pain and inflammation. Systemic inflammation is assessed using body temperature and haematological indicators of inflammation. The pathophysiological changes triggered by the pain model emulate those occurring as a result of routine husbandry procedures, demonstrating the relevance of this model to practical scenarios faced by veterinarians and farmers. 4 In a preliminary study using the model, the efficacy of meloxicam was assessed by administering the drug intravenously at the time of injecting turpentine, using a dosage of 1.0 mg/kg (Metacam 20 mg/mL Solution for Injection; Boehringer Ingelheim Animal Health, NSW, Aust). 4 Intravenous administration of meloxicam at the time of injecting turpentine was chosen in the preliminary trial as a route to optimise rapid tissue distribution of the drug. Treatment with meloxicam improved both the amount of weight borne by the turpentineinjected limb and tolerance to pressure exerted on the turpentineinjected limb and tended to reduce lameness assessed as animals walked down a race. 4 These data indicated the potential for an NSAID such as meloxicam to alleviate the pain associated with this model.
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The objective of the current study was to examine the dose-response to meloxicam for the relief of pain and inflammation and potential production-related consequences of the lameness model. Subcutaneous administration of meloxicam 90 min before injection of turpentine was chosen for the study in recognition that intravenous administration would not be a practical route if the drug were to be used under veterinary supervision by livestock producers and farm staff in the field. A 90-min pretreatment interval was chosen based on the expected pharmacokinetic profile of meloxicam. 5, 6 Doses of 0.5, 1.0 and 1.5 mg/kg meloxicam were chosen to cover the recommended dose in cattle (0.5 mg/kg), which is a dose reported to provide analgesic benefits in goat kids following disbudding, 7 and on the basis of the results of the preliminary study.
Materials and methods

Sheep
The experiment was undertaken at CSIRO's FD McMaster Laboratory in Armidale, New South Wales, and was approved by the institutional Animal Ethics Committee (Approval no. AEC09-13). The study was undertaken sequentially on two cohorts. In each cohort, 31 mature Merino ewes (36-58 kg) were housed in a group pen for several days to acclimatise them to hand feeding. During this time the sheep were vaccinated with a multivalent clostridial vaccine (Glanvac 6S Vaccine, Pfizer Animal Health, NSW, Aust) and drenched for internal parasites with Hat-Trick Triple Combination Drench for Sheep (Ancare Australia, NSW, Aust) at the manufacturer's recommended dose rate. The ewes were then moved to individual pens in a covered shed enclosed on three sides and open on the northern aspect. Sheep were fed 1.2 kg/day of a complete pelleted ration (Ridley Agriproducts, NSW, Aust: 20.6% crude protein dry matter; 12.5 MJ/kg dry matter) plus 200 g oaten chaff. Feed refusals were recorded each morning. Wool on the neck of each sheep, on a site anterior to the left shoulder, and on the anterior aspect of the forelimbs between the fetlock and coronet was removed with Oster clippers several days before the commencement of each trial to facilitate injections and blood collection.
Sheep were trained to walk from their home pen down a race to stand on a weighing platform then return to their home pen via a race 10 m long × 1 m wide. The walls of the return race were covered in hessian cloth. Training was performed on at least 7 days over a 2-week interval once sheep were acclimatised to their pens before commencement of the study. In each cohort, 24 sheep with the shortest time to settle when standing on the weighing platform, thus enabling the digital display to report a weight for each forelimb (see below), and consistent daily feed intake were chosen for the study. Daily feed intake was determined by weighing residual feed left from the previous day's ration.
Measurement of weight exerted through each forelimb
The weight exerted by each forelimb was recorded on two platforms attached to digital weight displays (Tru-Test Eziweigh, NSW, Aust) with a resolution of 50 g as described previously. 4 Four simultaneous recordings on each forelimb were made at each measurement time point and averaged.
Skin temperature
The surface skin temperature was measured with an infrared thermometer (TFA Dostmann GmBH, Wertheim, Germany) with a resolution of 0.1 C. The thermometer was held at a distance of 200 mm from the skin surface while a laser location light was directed at the injection site or a matching site on the contralateral forelimb.
Circumference of the forelimbs Limb circumference was measured midway between the fetlock and the coronet on each forelimb to the nearest millimetre with the aid of a scrotal circumference measuring tape.
Nociception
Sensitivity of the forelimb to pressure was measured with an aesthesiometer as described previously. 4 Maximum pressure exerted by the device was 1 bar. The pressure at which the forelimb was moved in response to the mechanical stimulation was recorded to the nearest 0.05 bar with the aid of an analogue pressure gauge. One bar exerted by the pin in the aesthesiometer was equivalent to a force of approximately 1.4 kgF.
Haematology
Blood was collected in 4.5-mL EDTA vacutainers by jugular venepuncture via 20G 25-mm needles and processed in an automated haematology analyser (Cell Dyn 3500R, Abbott Diagnostics) calibrated for sheep blood. Tubes were spun at 1000g for 12 min and plasma transferred to tubes for storage at −18 C for analysis of haptoglobin.
Haptoglobin determination
Haptoglobin concentration in plasma was assessed as described previously. 8 The inter-plate coefficient of variation (CV) was determined for quality control samples containing 0.1, 0.046 and 0.018 mg/mL were 9.8%, 7.95 and 8.7%, respectively. Assays were repeated if CVs for quality controls exceeded 15%.
Body temperature
Body temperature was recorded every 5 min by temperature loggers (Dallas Thermocron iButton DS1921H/Z, Maxim Integrated Products, CA, USA) placed intravaginally. The variables calculated from these data were hourly average temperature, daily maximum temperature, daily minimum temperature, daily amplitude of temperature variation and daily area under the curve (AUC).
Time forelimb raised
The time for each forelimb was raised was determined by examining 30-s video images of each sheep recorded in its pen just before it walked to the weighing platform. From each video recording the time that weight was not borne on each forelimb was measured over a 20-s interval, after the sheep had settled and when it was standing relatively still.
Lameness score
Gait was scored as follows from video images of each sheep as it walked down the 10-m race after release from the weighing platform: score 0: no abnormality in gait; score 1: head or shoulder dropped on 1-2 strides; score 2: head or shoulder dropped on ≥ 3 strides; score 3: limb carried on 1-2 strides; score 4: limb carried on ≥ 3 strides.
Turpentine injection
A site was marked on the skin overlying the anterior aspect of the proximal phalanx on the pastern midway between the fetlock and the coronet on each forelimb. Oil of turpentine (0.1 mL, Sigma Aldrich, MO, USA) was injected subcutaneously via a 25G needle at the marked site on one limb. The contralateral limb served as a control and received no injection. Injection of turpentine was alternated between the left and right forelimb of each cohort.
Drug treatments
Pens in the animal house were arranged in four blocks of six. Within each block, animals were allocated randomly to one of the four treatment groups by drawing a card with numbers 1-4 from a hat so that in each block there were two animals from two treatments and one animal from each of the other two treatments. A separate randomisation of treatments to pens was performed for each block within each replicate to ensure that six animals from each treatment were present in each cohort. Within each treatment, equal numbers of animals received oil of turpentine into the right or left front leg. Blinding Randomisation was performed by the officer administering the meloxicam and saline drug treatments. Personnel performing experimental measurements and clinical assessments were not informed of the allocation of animals to treatments.
Sampling regimen
Feed intake was recorded daily. Forelimb weights, skin temperature, forelimb circumference, forelimb sensitivity and haematology were assessed 18 h prior to meloxicam administration and then 3, 6, 9, 12, 24, 48 and 72 h after meloxicam administration. Body weight was recorded 1 day before and 7 days after meloxicam administration. Body temperature was recorded from −24 h before meloxicam administration through till 72 h afterwards.
Statistical analysis
Variables measured repeatedly over time were analysed by ANOVA for repeated measures, whereas variables such as cumulative lameness score that were not repeated over time were analysed by ANOVA. Fixed effects fitted to the models were cohort (2 levels) and drug treatment (4 levels: 0, 0.5, 1.0, 1.5 mg/kg meloxicam), and for repeated measures, time and time by treatment interaction. The cohort by treatment interaction was found to be not significant and was not included in the final models used. Values measured at −18 h were fitted as a covariate when significant. Residuals from fitting the model were checked for normality of distribution. Haematology data and the cumulative time forelimbs were raised were log 10 transformed to normalise the distribution of residuals. When treatment was included in the model, residuals for skin temperature of the turpentine-injected limb, daily feed intake, body weight change and haptoglobin were not normalised by transformation, therefore the effect of treatment was analysed by the non-parametric Kruskal-Wallis one-way ANOVA on ranks at each time point. Change in feed intake from day-to-day in the study was analysed by the non-parametric Wilcoxon signed ranks test. For all tests, differences were considered to be statistically significant if P ≤ 0.05. A trend towards significance was indicated when 0.1 > P > 0.5. The statistical experimental unit was the individual animal. The software package used for data analyses was Systat version 9 (SPSS Inc.).
Results
Pain-related variables
Forelimb weight-bearing. Weight exerted on the turpentinetreated limb was at a minimum 3 h post-drug administration (1.5 h post pain induction) (Figure 1 ). There was a corresponding increase in the weight exerted on the contralateral control limb at this time. Weights returned towards pre-turpentine treatment values by 12 h after drug administration, then dipped again at 24 h.
There was a tendency (P = 0.065) for drug treatment to affect the weight borne on the turpentine-treated limb across all time points and a significant treatment by time interaction (P = 0.047) for this variable (Figure 1 ). Meloxicam 1.0 mg/kg increased the weight borne on the turpentine-treated limb in comparison with all other treatments at 6 h post-administration and significantly increased the weight borne on the turpentine-treated limb in comparison with saline treatment at 9 h and 48 h post-administration.
There was a significant effect (P = 0.030) of drug treatment on the weight borne on the contralateral control limb across all time points, but no significant treatment by time interaction (P = 0.107) for this variable (Figure 1 ). There was a significant effect (P = 0.016) of drug treatment on the difference in weight borne by the turpentine and control limbs across all time points and a tendency towards a significant treatment by time interaction (P = 0.071) for this variable (Figure 1 ).
The main effect of drug treatment across time points for the three variables describing forelimb weight is illustrated in Figure 1 . The strongest effect was observed for the meloxicam 1.0 mg/kg dosage. In this group, more weight was borne on the turpentine-treated limb, less weight on the control limb and the difference in weight between forelimbs was less than for the saline and meloxicam 1.5 mg/kg groups. Meloxicam 0.5 mg/kg and 1.0 mg/kg did not differ. At a dosage of 1.0 mg/kg, meloxicam improved the weight borne on the turpentine-treated limb by 14% in comparison with saline.
Weight-bearing assessed from video images. The duration for which each forelimb was held in a non-weight-bearing posture during a 20-s segment of video image is presented in Figure 2 . The peak duration for which the turpentine-treated limb was raised occurred 3 h after drug (meloxicam or saline) administration. Distribution of residuals at each time point could not be normalised by transformation, so the cumulative time across the eight observation time points for which each foot was raised was calculated. There was a significant effect of drug treatment on the cumulative time the turpentine-treated limb was raised (P = 0.036) and a tendency towards a significant difference between turpentine-treated minus control limb values (P = 0.082, Figure 2) . Meloxicam given at a dosage of 0. Lameness scored from video images. Lameness score showed a biphasic pattern, with peaks at 3 and 24 h after drug administration as assessed when sheep walked down the race (Figure 3 ). There was a tendency towards a significant effect of drug treatment on lameness score (P = 0.054) across all time points, but no significant Limb sensitivity. The tolerance of turpentine-treated limbs to mechanical pressure from the aesthesiometer was lowest 3 h after drug administration and gradually increased over subsequent time points (Figure 4 ). There was a significant effect across all time points of drug administration on tolerance to pressure in turpentine-treated limbs (P = 0.042) and in the difference between turpentine-treated and control limbs (P = 0.006), but not in control limbs (P = 0.719). Treatment by time interactions were not significant (turpentinetreated limbs, P = 0.141; control limbs, P = 0.788; difference between limbs, P = 0.164). The 1.0 mg/kg dosage of meloxicam increased the mean tolerance to pressure in comparison with saline. The 0.5 and 1.5 mg/kg dosages were intermediate between saline and the 1.0 mg/kg dosage and did not differ from either. A similar pattern was observed for the difference between limbs in tolerance to pressure, with the exception that the 1.5 mg/kg dosage was also significantly superior to saline. At a dose rate of 1.0 mg/kg, meloxicam improved mean tolerance to pressure by 52% in comparison with saline. Treatments without a common letter are significantly different.
Inflammation-related variables
Skin temperature. Turpentine injection induced an increase in skin temperature that peaked at 33.2 AE 0.47 C 12 h after drug administration ( Figure 5 ). Distribution of residuals in turpentinetreated limbs could not be normalised by transformation, so the data were analysed within time points by the Kruskal-Wallis nonparametric test. There were no significant effects of drug treatment on the skin temperature of the turpentine-treated limb. Skin temperature at −18 h was a significant covariate for skin temperature in the control limbs (P = 0.041, data not shown) and the difference in temperature between limbs at −18 h was a significant covariate for the difference in skin temperature between turpentine-treated and control limbs (P = 0.047, data not shown). There were no significant effects of drug administration on skin temperature in control limbs (P = 0.453, data not shown) or the difference between limbs in skin temperature (P = 0.890, data not shown).
Limb circumference. In turpentine-treated limbs, limb circumference increased gradually throughout the observation period ( Figure 5 ). Limb circumference at −18 h was a significant covariate for later limb circumference in turpentine-treated (P < 0.001) and control limbs (P < 0.001, data not shown), but not for the difference between limbs (P = 0.188, data not shown). There was neither a significant effect of drug treatment on limb circumference (P = 0.513) nor a significant treatment by time interaction (P = 0.676) in turpentinetreated limbs. In control limbs, there was a tendency towards a significant effect of drug treatment on limb circumference (P = 0.076), but no significant treatment by time interaction (P = 0.759). There was no significant effect of drug treatment on the difference in circumference between limbs (P = 0.995, data not shown) or a significant treatment by time interaction (P = 0.373, data not shown).
Body temperature. Body temperature increased by approximately 0. 4 C following administration of turpentine and the strong circadian pattern of daily temperature variation was disrupted ( Figure 5 ). There was no significant effect of drug administration on daily maximum body temperature (P = 0.290, data not shown), daily minimum temperature (P = 0.617, data not shown), daily amplitude (P = 0.240, data not shown) or daily AUC (P = 0.855, data not shown), and treatment by time interactions were also not significant (P = 0.943, 0.306, 0.789, 0.206, respectively).
Haematology. Administration of turpentine caused no change in total leucocyte count (P = 0.170, data not shown), an increase in neutrophil count (P < 0.001, data not shown), a decrease in lymphocyte count (P < 0.001, data not shown) and an increase in the neutrophil to lymphocyte ratio (P = 0.008, Figure 5) . Values recorded at −18 hours were significant covariates for each haematological variable. There were neither significant effects of drug administration (P = 0.132, 0.157, 0.549, 0.762, respectively) nor any significant treatment by time interactions for these haematological variables (P = 0.207, 0.162, 0.116 and 0.956, respectively).
Haptoglobin. Haptoglobin concentrations in plasma increased
24 h after administration of turpentine and remained elevated for the remainder of the observation period (P < 0.001, data not shown). There were no significant effects of drug treatment on haptoglobin concentrations (P = 0.784). Figure 5 . Dose-response effect of meloxicam and control (saline) drug treatments (n = 12 per group) on circumference and skin temperature of the turpentine-injected limb, neutrophil to lymphocyte ratio in blood and body temperature. Data for circumference and skin temperature are least squares means AE SEM; data for neutrophil to lymphocyte ratio are back-transform means (SEM not shown); data for body temperature are raw means (SEM not shown). There were no significant effects of drug treatment on these variables (see text for P values).
Production-related variables
Daily feed intake. There was a small but significant reduction of feed intake (−39 g, P = 0.017; −88 g, P < 0.001; −59 g, P = 0.002) at 24, 48 and 72 h, respectively, following turpentine injection. Feed intake in some animals in all treatment groups decreased on these days (intake range 366-1200 g). There were no significant effects of drug administration on daily feed intake.
Body weight change. There was a significant increase in body weight (0.458 AE 0.166 kg; P = 0.008) from day −1 to day 7 (range −4.4 to +2.5 kg). There were no significant effects of drug administration on body weight change.
Discussion
The provision of effective analgesia for common husbandry practices is important in managing animal welfare and is recognised in published guidelines and policies. 9, 10 Successful control of pain requires consideration not only of the magnitude of analgesia provided, but also its duration. Until recently, the only registered option for sheep veterinarians and producers was relatively short-acting topically applied local anaesthetics. NSAIDs, such as meloxicam, have demonstrated sustained efficacy in a variety of species and are a mainstay of pain management in veterinary medicine. 11 The purpose of the current study was to investigate the efficacy of meloxicam in managing pain in sheep through the use of a validated pain model.
In this study, turpentine injection induced signs of acute inflammation, including tissue swelling, raised skin temperature, raised body temperature, leucocytosis and an increase in the neutrophil to lymphocyte ratio. Turpentine-induced signs of pain included reluctance to bear weight on the affected limb, allodynia, hyperalgesia and lameness, as well as reduced daily feed intake. These effects were consistent with earlier studies on the development of the turpentine model in sheep. 4 Treatment with meloxicam alleviated pain induced by experimental injection of turpentine. All pain-related variables showed improvement, with the strongest effects of meloxicam treatment occurring from 6 to 9 h after its administration. The painrelated variables ameliorated by meloxicam were weight exerted on forelimbs, time the turpentine-injected limb was held in a nonweight-bearing posture, lameness score assessed as sheep walked down a race and tolerance of the turpentine-treated limb to pressure exerted by an aesthesiometer. Greatest efficacy of meloxicam was displayed at the dosage of 1.0 mg/kg. There was a tendency for a dose-response effect between 0.5 and 1.0 mg/kg. Among the painrelated variables, the lower meloxicam dose reduced the time the turpentine-injected limb was held in a non-weight-bearing posture. Greater improvement in pain-related variables was not seen for meloxicam administered at a dosage of 1.5 mg/kg compared with 1.0 mg/kg. No significant effects of meloxicam on inflammatory variables or appetite were observed.
The results were consistent with a previous study of the efficacy of meloxicam in the turpentine lameness model in sheep. In the earlier study with smaller group sizes, meloxicam 1.0 mg/kg administered intravenously at the time of injection of turpentine was observed to improve tolerance to pressure in the injected limb at 24 h and the weight borne on the injected limb at 6 and 8 h, and tended to improve lameness score at 8 and 24 h. 4 Response of sheep to noxious mechanical nociceptive stimuli has been the subject of a number of studies. [12] [13] [14] [15] [16] [17] The aesthesiometer used in the current study was similar to that used by these other researchers. Slightly contradictory results have been reported on the effect of NSAIDs on the threshold to noxious mechanical stimulation. Welsh and Nolan noted that flunixin meglumine had no effect on the thresholds in healthy sheep tested over a 6-h period or in lame sheep suffering from foot rot during a 30-min study, although repeated dosing of lame sheep with flunixin increased thresholds over a 3-day period. 13 In contrast, Chambers et al. observed an increased threshold in both healthy and lame sheep receiving flunixin and dipyrone. 16 Higher maximal forces were used by both these groups of researchers compared with the current study in which no increase in threshold in healthy limbs of sheep receiving meloxicam was observed. The difference in methodology might account for the analgesic effect of NSAIDs to a noxious mechanical stimulus observed by Chambers et al. in healthy sheep.
Analgesic effects of meloxicam have been described in lameness models in cats, 18 dogs 19 and horses 20 and in numerous studies of clinical lameness in domestic animals; the anti-inflammatory effects of meloxicam have also been frequently noted. In a urate crystal model of lameness in cats, meloxicam reduced stifle swelling but did not reduce skin temperature. 18 In an endotoxin model of acute synovitis in the horse, 20 meloxicam reduced the volume of joint effusion and production of inflammatory mediators, including prostaglandin E 2 (PGE 2 ), matrix metalloproteases and substance P, and tended to reduce carpal circumference, but did not reduce the leukocyte influx into synovial fluid. PGE 2 produced through activity of cyclo-oxygenase-2 (COX-2) plays a central role in inflammatory responses. The ability of meloxicam to act as a COX-2 inhibitor in sheep is well described. 21 In a model of preterm labour in sheep, inhibition of PGE 2 production by meloxicam was used to inhibit uterine contraction. 22, 23 Sustained infusion of meloxicam was required for this effect and for inhibition of inducible COX-2 as assessed by protein expression. Cumulative drug doses administered to sheep in that study were not described; however, over a 10-h period it appears as though in excess of 12 mg/kg was needed for effective inhibition of PGE 2 production. These findings suggest that substantially higher doses of meloxicam than were used in the current study may be needed to inhibit the inflammatory effects of turpentine injection.
Turpentine injection increased maximum body temperature by approximately 0.4 C and decreased the amplitude of circadian temperature fluctuations. This change is characteristic of changes in body temperature induced through production of pro-inflammatory cytokines and PGE 2 during infection and inflammation rather than by stress-induced hyperthermia, which is driven by activation of the autonomic nervous system. 24 The former is inhibited by NSAIDs, whereas the latter is not. 24 Increased body temperature has been reported following injection of turpentine into the hock joint of steers 25 and in mice. 26 In a model of sterile inflammation in rats induced by macrophage-activating lipopeptide-2, meloxicam attenuated, but did not abolish, the increase in body temperature. 27 In a model of fever induced by intravenous injection of bacterial endotoxin in four heifers that acted as their own controls, pretreatment of the heifers with meloxicam before administration of endotoxin did not reduce the severity of fever. 28 However, in cats (n = 12 in a cross-over design) meloxicam exhibited a dose-dependent inhibition of endotoxin-induced fever 29 and in rats meloxicam reduced the severity of fever induced by injection of yeast. 30 In clinical disease settings, meloxicam induced significantly greater reduction in rectal temperature in feedlot heifers diagnosed with bovine respiratory disease than did flunixin 31 and a significant reduction in rectal temperature in sows suffering mastitis-metritis-agalactia syndrome. 32 In contrast, meloxicam treatment of pigs did not control the increase in rectal temperature observed in a model of respiratory disease induced by intrabronchial infusion of porcine reproductive and respiratory syndrome virus and endotoxin. 33 In the current study, turpentine injection induced a pronounced leucocytosis and increase in the neutrophil to lymphocyte ratio that was not reduced by meloxicam treatment. In the endotoxin challenge model in heifers noted before, 28 meloxicam reduced the magnitude of neutrophilia following endotoxin injection, whereas in the joint effusion model in horses there was no effect of meloxicam on synovial leucocytosis. 20 It is noteworthy that tissue inflammation and oedema are also induced by non-PGE 2 dependent pathways. 6 Furthermore, the potency for analgesic and antipyretic effects of NSAIDs is generally greater than their potency for antiinflammatory effects. In the current study, timing of administration of meloxicam may have been inappropriate to mitigate inflammatory events in this acute pain model. An analgesic benefit of the highest dosage of meloxicam used in the study, 1.5 mg/kg, was observed for only one of the four pain-related variables. Individual responses in this group were highly variable and one animal in the group had the highest mean lameness score, highest time the turpentine-treated limb was held in a non-weightbearing posture and ranked second lowest for weight borne on the treated limb. There were no obvious biological or methodological explanations for the failure of this animal to respond to meloxicam treatment and therefore no rationale to exclude the animal from the analyses. Despite this, the absence of additional benefits from this highest dose of meloxicam indicates that a dosage of 1.0 mg/kg is appropriate for reducing pain associated with turpentine injection.
Pain, inflammation and fever are common sequelae to surgical husbandry procedures and accompany many clinical infections in sheep. For example, husbandry procedures in sheep can induce active pain avoidance behaviours lasting several hours (ring and knife castration, mulesing), postural changes lasting at least 2 days (knife castration, mulesing, caesarean section), hormonal responses (castration, tail docking, mulesing, shearing, hoof trimming, general surgery), subfever elevated body temperature lasting several days (knife castration, mulesing), fever lasting 24 h (mulesing), local tissue swelling and inflammatory cell accumulation (castration, tail docking, mulesing) and systemic inflammation (tail docking, castration, mulesing). Turpentine injection emulated this general pattern of host responses to surgical husbandry procedures. 4 Each model used to assess the efficacy of NSAIDs has strengths and weakness and no single model can combine all the types of pain and inflammation for which NSAIDs might provide clinical benefit. The turpentine model using penned sheep allows very close observation and objective quantification of variables indicative of local and systemic inflammation, fever, loss of function and pain. It enables multimodal assessment of pain by combining subjective scores of behaviour, such as lameness score as sheep move down a lane, with objective quantification of weight borne on the affected limb. In addition, it overcomes the limitations of field-based methods for assessing the efficacy of NSAIDs; for example, the lack of opportunity for the quantitative assessment of pain-related behaviours, tissue swelling and temperature, and for the regular collection of blood samples to allow monitoring of the systemic signs of inflammation.
The results presented here demonstrated that a dosage of 1.0 mg/kg meloxicam given to sheep was effective at alleviating pain caused by injection of turpentine as assessed by all four pain-related variables measured in this study. Extension of these findings into veterinary practice, particularly as related to routine husbandry procedures, will have a positive effect on the welfare of this important production animal species.
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